Covidien

Morgan Stanley has raised the price target on Covidien (NYSE: COV) from $60 to $63 and maintains its Overweight rating.

Deutsche Bank is out with its report today on Covidien (NYSE: COV), raising its PT from $60 to $61. In a note to clients, Deutsche Bank writes, "All divisions came in better than expected, notably med devices and pharma. Organic growth looks to be around 4%-5%, an improvement off F1Q's 3% rate....

Morgan Stanley is providing some highlights from Covidien's (NYSE: COV) analyst day. “Covidien surprises in surgical dissection and sealing,” Morgan Stanley writes. “Further insights from SAGES are forthcoming but we wanted to highlight two points from Covidien's analyst day. “While we expected...

According to J.P. Morgan, Covidien (NYSE: COV) Overweight rating is reiterated. J.P. Morgan reported that the 2011 SAGES meeting is underway in San Antonio. “In the Endo-Mechanical markets, J&J has stolen the headlines at this year's meeting, introducing the first power stapler, while Covidien...

In a report published by Jefferies, Covidien (NYSE: COV) saw FDA Briefing Documents support a positive panel vote and FDA clearance of eV3's PED device. Jefferies said that PED approval would strengthen COV's positioning in the $1.3B neurovascular market, generating sooner than expected ROIC on...

Piper Jaffray has published a research report on Covidien, Ltd. (NYSE: COV) after the company reported a strong, in-line quarter with revenues coming in with what analysts expected. In the report, Piper Jaffray writes "Revenues were in line with what we expected at $2.77B (up 5%); medical devices...

Piper Jaffray has raised the price target on Covidien, Ltd. (NYSE: COV) from $53 to $56 and maintains its Overweight rating.

Deutsche Bank has published a research report on Covidien Ltd. (NYSE: COV) after the company reported 1Q11 earnings that were higher than expectations. In the report, Deutsche Bank writes that "F1Q11 sales and EPS ahead of Consensus. Med Device & Pharma were better (very good), Med supplies...

Goldman Sachs has published a research report on Covidien (NYSE: COV) after the company reported 1Q2011 EPS this morning that beat analyst estimates. In the report, Goldman Sachs writes that "This morning, Covidien reported adjusted 1QFY2011 EPS of $0.95 (+14% yoy) vs. our estimate of $0.80 and...

Jefferies is raising its PT on Covidien (NYSE: COV) $56 from $52.

Citigroup has raised the price target on Covidien Ltd. (NYSE: COV) from $52 to $58 and maintains its Buy rating.

JP Morgan has published a research report on Covidien (NYSE: COV) and has updated the model forecast for 2011. In the report, JP Morgan writes "Our FY11 forecast calls for revenues of $11.35B (+8.8% reported, +2.6% organic) and EPS of $3.62 (+6.9%). For F1Q, we forecast revenues of $2.727B (+3.1%...

Morgan Keegan is out with its report on Covidien (NYSE: COV) noting speculation by investors that Covidien might sell off its pharmaceutical assets. In a note to clients, Morgan Keegan writes, "Based on our analysis, we believe that Covidien should exit the pharmaceutical business over time as it...

In a report released this morning, Jefferies & Company said that it is raising its Covidien (NYSE: COV) price target to $52. “Our fundamental thesis regarding the company's ability to maintain and drive further margin expansion both organically and through acquisition remains intact,” Jefferies...

Covidien PLC (NYSE: COV) guided sales growth of 6-9%, operating margins of 21-22%, and a tax rate of 20-21%, and as a result, JP Morgan continues to believe that its F2011 EPS estimate of $3.48 is achievable and is open for share repurchase discussion. EPS estimates for F2010 are currently $3.27,...